IOP lowered with trab and combination trab

Article

IOP is successfully reduced with both trabeculectomy and combined trabeculotomy-trabeculectomy with mitomycin C in children with glaucoma.

IOP is successfully reduced with both trabeculectomy and combined trabeculotomy-trabeculectomy with mitomycin C in children with glaucoma.

The retrospective, comparative study, led by Dr Peter A. Netland, Department of Ophthalmology (SDL), University of North Carolina, Chapel Hill, North Carolina, USA, included 40 eyes of 33 glaucoma patients.

Trabeculectomy was performed on 17 eyes (Group 1) and 23 eyes underwent combined trabeculotomy-trabeculectomy (Group 2), with mitomycin C administered to all patients. Successful surgery was defined if IOP was 21 mmHg or less and greater than 5 mmHg without additional surgery.

No significant difference in mean IOP reduction was found between the groups during follow-up. There was a higher success rate after surgery in group 2, compared to group 1. There were five treatment failures in group 1 and two in group 2. The failures were caused increased IOP or hypotony and there were no complications observed.

Both procedures are equally effective in lowering average IOP in children with glaucoma, but combined trabeculotomy-trabeculectomy was linked to greater long-term successful outcomes.

More detailed information may be found at the Journal of Paediatric Ophthalmology and Strabismus, click here

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.